HK Stock Market Move | CRO concept stocks are performing strongly, the BIO conference highlights the global competitiveness of Chinese CXOs, and the pharmaceutical field has made new breakthroughs with increased openness.

CRO concept stocks perform strongly. As of the time of writing, Asymchem Laboratories (06821) rose by 12.09% to 108.5 Hong Kong dollars; GENSCRIPT BIO (01548) rose by 8.56% to 11.8 Hong Kong dollars; Hangzhou Tigermed Consulting (03347) rose by 7.88% to 33.42 Hong Kong dollars; and WuXi AppTec (02359) rose by 8.18% to 141.8 Hong Kong dollars. On the news front, the BIO 2026 International Biotechnology Conference was held in San Diego, USA from June 22 to 25, and China's CXO companies' high efficiency advantages have gained global recognition, further expanding overseas order opportunities. In addition, three departments jointly issued the "Action Plan to Utilize Foreign Investment to Ensure Stability and Promote Excellence," clearly stating that efforts will be made to research and formulate detailed regulations for segmented production of drugs, facilitating overseas drug market authorization holders to carry out segmented production of biological products and chemical drugs. Orient released a research report stating that based on the latest data on key indicators of CXO business sentiment: in the first five months of 2026, various factors related to domestic funding, research and development, and orders have resonated upwards, indicating a sustained high level of business sentiment in the domestic CXO industry. The bank believes that domestic CXO companies have sufficient orders, and with the conversion of orders into execution, there will be a significant improvement in financial performance.